Skip to main content
PIRAMAL PHARMA LIMITED logo

PIRAMAL PHARMA LIMITED — Investor Relations & Filings

Ticker · PPLPHARMA ISIN · INE0DK501011 LEI · 3358006D6AL7PZ4U9T51 BSE.NS Manufacturing
Open in API
Filings indexed 365 across all filing types
Latest filing 2024-08-05 Regulatory Filings
Country IN India
Listing BSE.NS PPLPHARMA

About PIRAMAL PHARMA LIMITED

https://www.piramalpharma.com/

Piramal Pharma Limited provides a broad range of products and services across the drug lifecycle through three main business segments: Piramal Pharma Solutions, Piramal Critical Care, and Consumer Healthcare. Piramal Pharma Solutions operates as an integrated Contract Development and Manufacturing Organization (CDMO), offering end-to-end services from drug discovery and development to commercial manufacturing of APIs and formulations. Piramal Critical Care focuses on complex hospital generics, holding a significant global market share in inhalation anesthetics, including Sevoflurane and Isoflurane, as well as injectable anesthesia and pain management therapies. The Consumer Healthcare division manages a diverse portfolio of over-the-counter brands such as Saridon, Lacto Calamine, and Tetmosol. The company leverages an extensive global manufacturing network to deliver specialized healthcare solutions worldwide.

Recent filings

Filing Released Lang Actions
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a short notice dated 5th August 2024, addressed to stock exchanges (BSE and NSE) regarding the schedule of upcoming analyst and institutional investor meetings. It references SEBI regulations for disclosure but does not contain any financial data, results, or detailed reports. The document is essentially an announcement of scheduled investor meetings, not a financial report, earnings release, or management discussion. Given the content and length (1671 characters), it fits best under the category of Investor Presentation announcements or related updates. However, since it is only a schedule notification and not a detailed presentation, the closest fitting category is Regulatory Filings (RNS) as a general regulatory announcement about investor meetings under SEBI regulations.
2024-08-05 English
Credit Rating
Regulatory Filings Classification · 95% confidence The document is an intimation under Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements, 2015. It informs about the credit rating reaffirmation and outlook revision by CARE Ratings Limited for various bank facilities and instruments of Piramal Pharma Limited. The document is short (1775 characters) and serves as a regulatory announcement of a rating update rather than a financial report or detailed analysis. It does not contain financial statements, management discussion, or detailed financial data. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2024-08-01 English
Updates
Capital/Financing Update Classification · 95% confidence The document is a notification under Regulation 30 of the SEBI Listing Regulations about the sale of a company unit. It is an announcement of a corporate transaction (sale of a unit) approved by the Board's Administrative Committee. The document does not contain financial statements or detailed financial analysis, nor is it a full report. It is a regulatory announcement about a capital asset sale, which fits best under Capital/Financing Update (CAP). The document length is short (2174 characters), and it is not a report publication announcement or certification. Therefore, the classification is CAP with high confidence.
2024-07-30 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges regarding the transcript of a conference call on the unaudited financial results for the quarter ended June 30, 2024. It references the transcript of the conference call held on July 26, 2024, and states that the transcript is available on the company's website. The document itself does not contain the transcript text but is an announcement about the availability of the transcript. Given the document length is only 1430 characters and it is primarily an announcement of the transcript's availability, it fits the category of a Regulatory Filing (RNS) rather than a full Call Transcript (CT).
2024-07-29 English
Shareholders meeting
Regulatory Filings
2024-07-26 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a short announcement dated 26th July 2024, addressed to stock exchanges, regarding the availability of the audio recording of a conference call on the unaudited financial results for the quarter ended 30th June 2024. It references a previous letter and provides a link to the company's website where the recording can be accessed. The document does not contain the transcript itself or detailed financial data, but rather informs about the availability of the conference call recording. According to the classification rules, such announcements about availability of conference call recordings are best classified as Call Transcript (CT) since it relates directly to the conference call content. However, since this document only announces the recording availability and does not contain the transcript, it is more appropriate to classify it as Regulatory Filings (RNS) as a general regulatory announcement. The document length is short (1436 characters), and it does not contain the transcript or financial data itself, so it is not a full Call Transcript (CT). Therefore, the best fit is Regulatory Filings (RNS).
2024-07-26 English

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.